Champions Oncology (CSBR) Receivables - Net (2011 - 2026)

Champions Oncology has reported Receivables - Net for 16 years, with the latest figure at $14.2 million in Q2 2026.

• On a quarterly basis, Receivables - Net rose 16.37% year-over-year to $14.2 million in Q2 2026; TTM through Apr 2026 was $14.2 million, a 16.37% increase from a year earlier, with the FY2026 full-year figure at $14.2 million, up 16.37% from the prior year.
• Receivables - Net was $14.2 million for Q2 2026 at Champions Oncology, up from $13.1 million in the prior quarter.
• The five-year high for Receivables - Net was $16.8 million in Q1 2025, with the low at $7.7 million in Q4 2023.
• Average Receivables - Net over 5 years is $10.7 million, with a median of $10.2 million recorded in 2022.
• The sharpest annual moves came in 2025 and 2026: Receivables - Net jumped 85.58% in 2025, then slipped 22.14% in 2026.
• Over 5 years, Receivables - Net stood at $9.0 million in 2022, then fell by 14.44% to $7.7 million in 2023, then soared by 49.23% to $11.5 million in 2024, then grew by 9.23% to $12.6 million in 2025, then advanced by 13.41% to $14.2 million in 2026.
• The last three Receivables - Net figures came in at $14.2 million (Q2 2026), $13.1 million (Q1 2026), and $12.6 million (Q4 2025), per Business Quant data.